Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More

Invitrogen™ Human ARHGEF17 Synthetic Peptide

Catalog No. PEP0557
Click to view available options
Quantity:
50 μg

Synthetic Peptide

TEM4 Synthetic Peptide, PEP-0557, from Invitrogen.

Rho GTPases, which are activated by specific guanine-nucleotide exchange factors (GEFs), play pivotal roles in several cellular functions. TEM4, encoding a protein containing 1510 amino acids, contains a RhoGEF-specific Dbl homology (DH) domain but lacks their typical pleckstrin homology domain. TEM4 is a Rho-specific GEF with novel structural and regulatory properties and predominant expression in the heart. It couples tyrosine kinase signals with the activation of the rho/rac GTPases, thus leading to cell differentiation and/or proliferation. Elevated levels of TEM4, TEM5, TEM6, TEM7 and TEM7R were also raised in breast cancer tissues. TEM4 could also prove to be useful targets therapeutically.
TRUSTED_SUSTAINABILITY

Specifications

Gene ID (Entrez) 9828
Species Human
Purification Method purified
Accession Number Q96PE2
Common Name Human ARHGEF17
Concentration 200 μg/mL
Content And Storage -20°C
Description Synthetic Peptide
Format Liquid
Formulation PBS with 0.1% BSA and 0.02% sodium azide; pH 7.2
For Use With (Application) Blocking Assay, Control
Gene Symbol ARHGEF17
Lyophilized No
Preservative 0.02% sodium azide
Product Type Peptide
Quantity 50 μg
Regulatory Status RUO - research use only
Storage Buffer PBS
Show More Show Less
WARNING: Cancer - www.P65Warnings.ca.gov
Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Your feedback has been submitted: Thank you for helping us improve our website.